Can the AstraZeneca share price continue to smash the FTSE 100?

G A Chester discusses the valuation and prospects of FTSE 100 (INDEXFTSE:UKX) pharma stock AstraZeneca plc (LON:AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE: AZN) share price has been making new all-time highs in recent weeks. It’s up 21% year to date, compared with a 9% decline for the FTSE 100. And over the past five years it’s climbed 87% versus a 5% gain for the index. Do I think it can continue to smash the market?

Historically low base

The company released its Q3 results earlier this month, and chief executive Pascal Soriot told investors: “Today marks an important day for the future of AstraZeneca, with the performance in the quarter and year to date showing what we expect will be the start of a period of sustained growth for years to come.”

This growth would start from a historically low base. Over the last 12 months, the company generated $399m net cash from operations on revenue of $21.5bn. There was a time when it was generating in excess of $10bn cash a year. This last occurred in 2010 when it posted $10.7bn (on revenue of $33.3bn). After investing activities and dividends, it still had more than $1bn left to add to its cash pile. Net cash at the year-end stood at $3.7bn.

Should you invest £1,000 in Tullow Oil Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Tullow Oil Plc made the list?

See the 6 stocks

Roll on to 2013 when new boss Soriot delivered his first annual results, and the picture was already looking less rosy. Revenue had declined to $25.7bn, net cash from operations to $7.4bn and year-end net cash was just £39m. The table below shows some key numbers that illustrate the business’s continuing decline to where it is today.

  2014 2015 2016 2017 2018 (ytd) Total
Revenue ($bn) 26.1 24.7 23.0 22.5 15.7 112.0
Net cash inflow from operating activities ($bn) 7.1 3.3 4.1 3.6 0.4 18.5
Net cash inflow/(outflow) from investing activities (7.0) (4.2) (4.0) (2.3) 0.0 (17.5)
Dividends paid (£bn) (3.5) (3.5) (3.6) (3.5) (3.5) (17.6)

As you can see, revenue has fallen every year and net cash generated from operating activities has been a far cry from its heyday. Almost all the total of $18.5bn generated in the period has been ploughed back into investing activities ($17.5bn). This means that the business itself has supported just $1bn of the total of $17.6bn paid out in dividends. The company has simply been borrowing money and handing it over to shareholders. It’s gone from a net cash position of £39m at the start of 2014 to a net debt position of $16.2bn today.

Premium valuation

The impact of patent expiries on some of AstraZeneca’s key blockbuster drugs is now bottoming out. With new drugs coming through, the company is in a position to begin growing its top line again. However, it’s going to be quite some years before we see a return to anything like the aforementioned $33.3bn revenue and $10.7bn net cash generation we saw in 2010. As such, and with the company also having moved from a net cash position of $3.7bn in 2010 to that net debt of $16.2bn today, it seems strange to me that the shares have risen quite as far as they have. Indeed, the current price of 6,204p is more than double what it was when the company posted those impressive 2010 results.

The valuation today is 23.9 times current-year forecast earnings, falling to a still premium 21.6 next year on forecasts of 10.3% earnings growth. The price-to-earnings growth (PEG) ratio of 2.1 is well above the PEG ‘fair value’ marker of 1, while the dividend yields a below-market-average 3.5% and will need more borrowing to fund it in the near term. I believe the current valuation is too rich, so I’m avoiding the stock at this stage.

Should you invest £1,000 in Tullow Oil Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Tullow Oil Plc made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 investment trusts to help investors become Stocks & Shares ISA millionaires

One of the biggest challenges for new Stocks and Shares ISA investors is which investments to make. Dr James Fox…

Read more »

Investing Articles

The Greggs share price has plummeted for good reason! It’s now a proper dividend stock

Dr James Fox explores whether the beaten-down Greggs share price represents a potential buying opportunity or a value trap.

Read more »

Working from home due to social distancing
Investing Articles

A year ago, £10,000 in Tesco shares — at today’s price — is now worth…

Tesco's provided solid investor returns since April 2024 thanks to strong share price gains and healthy dividends. Can it keep…

Read more »

Investing Articles

Just released: our 3 top small-cap stocks to consider buying in April [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

Here’s why Tesla stock just rocketed 22.7%! Is it time to buy?

This writer wonders whether the news that sent Tesla stock soaring yesterday is a true gamechanger for the electric vehicle…

Read more »

Investing Articles

2 quality UK stocks to consider buying as share prices rally

With UK stocks moving higher, it might look as though investors with cash on hand have missed their chance. But…

Read more »

Investing Articles

How much £10,000 invested in Lloyds shares is forecast to be worth in 12 months

Harvey Jones is looking past today's stock market volatility to see where Lloyds shares may stand in a year's time.…

Read more »

Investing Articles

How Warren Buffett stays ahead of the stock market

When share prices fall, everyone suddenly wants to be like Warren Buffett. But what’s the secret to the Berkshire Hathaway…

Read more »